Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMX-049 Phase 1 Safety, Tolerability, PK/PD in Healthy Male Subjects
jRCT2080223411Phase 1
- Sponsor
- Teijin Pharma
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMX-049 in gout and hyperuricemia (4 arms), sponsored by Teijin Pharma. Primary endpoints: Safety and tolerability of TMX-049, Pharmacokinetics of TMX-049 and 1 more.
02
Drugs
TMX-049
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on jRCT2080223411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223411.